Mirna Therapeutics announced the completion of a $34.5 million Series C financing.
The company’s first institutional financing was led by Sofinnova Ventures, with participation from new investors, New Enterprise Associates , Pfizer Ventures, Osage University Partners, Correlation Ventures, and existing investors.
The financing will enable Mirna to advance its lead microRNA-based therapeutic product candidate MRX34 through human proof of concept studies.
“This significant round of financing is an important validation of the therapeutic and commercial potential of our differentiated miRNA replacement approach and underscores the promise of our pipeline of miRNA-based product candidates,” said Paul Lammers, M.D., Mirna’s President and Chief Executive Officer.
For further deal information visit Current Agreements (subscription required)
Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Financing Scorecard – view top life science financing deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity